Yahoo Search Búsqueda en la Web

  1. Se muestran resultados de

    adverse effect platinum nccn

Resultado de búsqueda

  1. 1 de mar. de 2020 · The NCCN Guidelines for Management of Immunotherapy-Related Toxicities provide interdisciplinary guidance on the management of immune-related adverse events (irAEs) resulting from cancer immunotherapy.

  2. 31 National Comprehensive Cancer Network. PMID: 35390769. DOI: 10.6004/jnccn.2022.0020. Abstract. The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to provide guidance on the management of immune-related adverse events resulting from cancer immunotherapy.

  3. 11 de mar. de 2019 · FULL TEXT. PDF. ARTICLE DETAILS. The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to provide guidance on the management of immune-related adverse events resulting from cancer immunotherapy.

  4. 1 de nov. de 2021 · How should clinicians manage immune-related adverse events (irAEs) in adult patients with cancer treated with immune checkpoint blockade antibodies therapy? Target Population Adult patients with cancer receiving treatment with immune checkpoint blockade inhibitors alone. Target Audience

  5. The NCCN Guidelines for Management of Immunotherapy-Related Toxicities provide interdisciplinary guidance on the management of immune-related adverse events (irAEs) resulting from cancer immunotherapy. These NCCN Guidelines Insights describe symptoms that may be caused by an irAE and should trigger …

  6. effects from immunotherapy can affect your whole body. • Side effects may appear shortly after beginning treatment, within the first couple of months, or even after you finish treatment. • Because many of these side effects can occur from other causes that would be treated differently, make sure your doctor knows you are or were on

  7. 22 de dic. de 2023 · AE, adverse event; BSC, best supportive care; CAV, cyclophosphamide/doxorubicin/vincristine; CTFI, chemotherapy-free interval; DoR, duration of response; ES, extensive stage; FDA, US Food and Drug Administration; IV, intravenous; LS, limited stage; NCCN, National Comprehensive Cancer Network; ORR, overall response rate; OS, overall ...